The qualitative assessment of optical coherence tomography and the central retinal sensitivity in patients with retinitis pigmentosa.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
02
2020
accepted:
19
04
2020
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
29
7
2020
Statut:
epublish
Résumé
To analyze the relationships between qualitative and quantitative parameters of spectral-domain optical coherence tomography (SD-OCT) and the central retinal sensitivity in patients with retinitis pigmentosa (RP). Ninety-three eyes of 93 patients were finally enrolled, with a median age (quartile) of 58 (24.5) years. We assessed the patients using SD-OCT and the 10-2 program of a Humphry Field Analyzer (HFA). As a qualitative parameter, two graders independently classified the patients' SD-OCT images into five severity grades (grades 1-5) based on the severity of damage to the photoreceptor inner and outer segments (IS/OS) layer. As quantitative parameters, we measured the IS-ellipsoid zone (IS-EZ) width, IS/OS thickness, outer nuclear layer (ONL) thickness, central macular thickness (CMT, 1 and 3 mm) and macular cube (6 × 6 mm) volume and thickness. The central retinal sensitivity was defined by the best-corrected visual acuity (BCVA; logMAR), average sensitivities of the central 4 (foveal sensitivity [FS]) and 12 (macular sensitivity [MS]) points of the HFA 10-2 program and the mean deviation (MD) of the 10-2 program. Spearman's correlation was used to assess the association between both qualitative and quantitative parameters and variables of the central retinal sensitivity. In addition, we performed a multiple regression analysis using these parameters to identify the parameters most strongly influencing the central retinal sensitivity. The IS/OS severity grade was significantly correlated with the BCVA (ρ = 0.741, P < 0.001), FS (ρ = -0.844, P < 0.001), MS (ρ = -0.820, P < 0.001) and MD (ρ = -0.681, P < 0.001) and showed stronger correlations to them than any other quantitative parameters including the IS-EZ width, IS/OS thickness, ONL thickness, CMTs and macular cube volume/thickness. Furthermore, a step-wise multiple regression analysis indicated that the IS/OS severity grade was more strongly associated with the BCVA (β = 0.659, P < 0.001), FS (β = -0.820, P < 0.001), MS (β = -0.820, P < 0.001) and MD (β = -0.674, P < 0.001) than any other quantitative parameters. The intraclass correlation coefficient between two graders indicated substantial correlation (κ = 0.70). The qualitative grading of OCT based on the severity of the IS/OS layer was simple and strongly correlated with the central retinal sensitivity in patients with RP. It may be useful to assess the central visual function in patients with RP, although there is some variation in severity within the same severity grade.
Identifiants
pubmed: 32392207
doi: 10.1371/journal.pone.0232700
pii: PONE-D-20-03802
pmc: PMC7213731
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0232700Déclaration de conflit d'intérêts
Mitsuru Nakazawa received research funds from Alcon (Tokyo, Japan), Novartis (Tokyo, Japan), Santen (Osaka, Japan), AMO (Tokyo, Japan), HOYA (Tokyo, Japan) and Pfizer (Tokyo, Japan). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Doc Ophthalmol. 2009 Feb;118(1):69-77
pubmed: 19030905
Biomed Opt Express. 2011 Sep 1;2(9):2493-503
pubmed: 21991543
JAMA Ophthalmol. 2013 Sep;131(9):1143-50
pubmed: 23828615
Invest Ophthalmol Vis Sci. 2009 May;50(5):2328-36
pubmed: 19011017
PLoS One. 2016 Feb 04;11(2):e0148022
pubmed: 26845445
Hum Gene Ther. 2019 Dec;30(12):1520-1530
pubmed: 31672061
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):1134-1143
pubmed: 29490351
Am J Ophthalmol. 2008 Sep;146(3):417-426
pubmed: 18635153
Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1378-1386
pubmed: 28253400
Biomed Opt Express. 2011 Apr 05;2(5):1106-14
pubmed: 21559123
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3617-21
pubmed: 18441301
Biomed Res Int. 2018 Nov 15;2018:5174986
pubmed: 30581855
PLoS One. 2018 Mar 9;13(3):e0193778
pubmed: 29522537
Int J Mol Sci. 2019 Mar 26;20(6):
pubmed: 30917587
J Ophthalmol. 2013;2013:821460
pubmed: 24368939
Eye (Lond). 2009 Feb;23(2):304-8
pubmed: 18188175
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3551-8
pubmed: 18441311
Br J Ophthalmol. 2009 Jan;93(1):126-7
pubmed: 19098050
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3469-3475
pubmed: 30025100
Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4213-9
pubmed: 20220048
Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3349-54
pubmed: 16123439
Eye (Lond). 2015 Jul;29(7):895-901
pubmed: 25952950
JAMA Ophthalmol. 2016 Jun 1;134(6):628-35
pubmed: 27031504
PLoS One. 2019 Dec 12;14(12):e0226097
pubmed: 31830067
Invest Ophthalmol Vis Sci. 2012 Feb 21;53(2):833-40
pubmed: 22247460
Am J Ophthalmol. 2006 Dec;142(6):945-52
pubmed: 17157580
Ophthalmologica. 2019;242(1):22-30
pubmed: 30893682
Biomed Res Int. 2019 Oct 30;2019:8276140
pubmed: 31781647
Sci Rep. 2018 May 23;8(1):8070
pubmed: 29795288
PLoS One. 2016 Sep 19;11(9):e0162835
pubmed: 27644042
BMC Ophthalmol. 2018 Jun 26;18(1):153
pubmed: 29940899
Ophthalmic Res. 2016;56(3):111-22
pubmed: 27352292
PLoS One. 2019 Jan 29;14(1):e0210439
pubmed: 30695025